Skip to content

Effect of Glutamine on Reducing Myocardial Damage

Evaluation of oral Glutamine administration on myocardial damage following non-st elevation myocardial infarction, Double blind randomized clinical trial study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20151109024975N12
Enrollment
106
Registered
2019-06-30
Start date
2018-11-22
Completion date
Unknown
Last updated
2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non ST elevation myocardial infarction. Acute coronary thrombosis not resulting in myocardial infarction

Interventions

Intervention 1: Intervention group: A dose of 0.5 g / kg of glutamine powder is administered orally once a day for 3 days of hospitalization. Intervention 2: Control group: Patients in the control g

Sponsors

Sari University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age over 18 years NSTEMI patients Normal function of liver, renal system, pulmonary system and thyroid

Exclusion criteria

Exclusion criteria: Emergency patients Serious water and electrolyte disorders Unwillingness to co-operate with the patient History of chronic lung, liver, kidney and thyroid diseases and heart failure Age over 80 years Pregnant and lactating women Patients who are hypersensitive to glutamine or who are banned in any way by their administration of glutamine Total Bilirubin more than 10 mg / dL Creatinine clearance less than 30 ml / min Absolute Absence of Intestinal Feeding

Design outcomes

Primary

MeasureTime frame
NonST elevation myocardial infarction. Timepoint: After diagnosis of myocardial infarction without ST elevation, an increase in Troponin and CK-MB in the first three days of hospitalization. Method of measurement: TIMI score.

Secondary

MeasureTime frame
Duration of admission to CCU. Timepoint: Duration of admission. Method of measurement: Patients follow up.;Mortality. Timepoint: Duration of admission. Method of measurement: Patients follow up.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGohar Eslami

Sari University of Medical Sciences

g.eslami@mazums.ac.ir+98 11 3354 3695

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026